Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Sanofi-Aventis S.A. ADR
(NQ:
SNY
)
56.21
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sanofi-Aventis S.A. ADR
< Previous
1
2
3
4
5
6
7
8
9
...
29
30
Next >
Sanofi's $20B Consumer Health Unit Sale: Goldman Sachs, Morgan Stanley Line Up $6.5B Financing
July 12, 2024
Explore the €6 billion financing effort by banks for Sanofi's consumer health division sale. Discover the latest in high-stakes pharmaceutical industry deals.
Via
Benzinga
Bernie Sanders Targets High Prices of Ozempic and Wegovy In US
July 11, 2024
Senator Bernie Sanders is pushing Novo Nordisk to lower U.S. prices for weight-loss drugs Ozempic and Wegovy, as part of a broader effort to reduce drug costs and expand Medicare price negotiations.
Via
Benzinga
EXCLUSIVE: VeeCon 2024 Announces Danica Patrick, Jerome Bettis, Paul Scheer, Mike Posner, Liquid Death CEO Mike Cessario As New Speakers
July 11, 2024
VeeCon will bring the best of business, pop culture and Web3 in a multi-day conference hosted by serial entrepreneur and VeeFriends founder Gary Vaynerchuk (aka Gary Vee) for a
Via
Benzinga
3 Stocks to Sell Immediately Based on the French Election Results
July 09, 2024
Discover why Engie S.A., Sanofi, and Carrefour are prime candidates for divestment post-French elections amid potential policy impacts.
Via
InvestorPlace
What The Quest For New Cholesterol Treatments Means For Novartis, Merck — And Patients
July 05, 2024
A number of companies are working on new drugs for high lipids, including cholesterol and triglycerides.
Via
Investor's Business Daily
Upcoming Stock Spinoffs: Should You Pounce or Pass?
July 04, 2024
Stock spinoffs are a unique opportunity to pick up unloved, unwanted businesses but patience is often needed before buying in.
Via
InvestorPlace
7 Safe Haven Stocks to Buy Before the Next Market Correction
July 03, 2024
Discover resilient safe haven stocks to weather economic fluctuations in restaurants, pharmaceuticals, household products, and retail.
Via
InvestorPlace
Europe Approves Sanofi/Regeneron's Dupixent for 'Smoker's Lungs' A Month After US FDA Asks For Data
July 03, 2024
EMA approves Dupixent (dupilumab) as an add-on maintenance treatment for adults with uncontrolled COPD characterized by raised blood eosinophils. This marks the first new treatment for COPD in over a...
Via
Benzinga
Exposures
Product Safety
Novavax’s Second Act: How a Fallen COVID Star Could Rise from the Ashes
July 03, 2024
After pulling back following May's "Sanofi surge," don't rule out the potential for further needle-moving news with Novavax stock.
Via
InvestorPlace
Exposures
COVID-19
Heartburn Drug Zantac Litigation: GSK And Other Pharma Giants Face Trial Over Cancer Claims
July 02, 2024
A Delaware judge dismissed GSK and other drugmakers' appeal, allowing over 70,000 lawsuits alleging Zantac causes cancer to proceed, with the companies needing Delaware Supreme Court approval to...
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
Surprise! 3 Stocks That Are Outperforming Nvidia in 2024.
July 01, 2024
There are more marketplace opportunities than just AI which is why these stocks that are outperforming Nvidia have done so well.
Via
InvestorPlace
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Sanofi Nears Decision on $1.6B Upgrade For Frankfurt Insulin Plant
July 01, 2024
Sanofi is set to invest up to $1.6 billion in its Frankfurt insulin production site, marking a significant win for Germany's healthcare sector. Recent investments by Daiichi Sankyo and Eli Lilly...
Via
Benzinga
Where Will Novavax Be in 1 Year?
June 29, 2024
We will know a lot more about the vaccine maker's long-term prospects in 12 months.
Via
The Motley Fool
First Inhaled COPD Therapy In Over 2 Decades - FDA Approves Verona Pharma's First Commercial Product
June 27, 2024
The FDA has approved Verona Pharma's Ohtuvayre (ensifentrine) as maintenance treatment of chronic obstructive pulmonary disease in adults. The drug could generate $3.6 billion in peak sales.
Via
Benzinga
Exposures
Product Safety
Why Is Vigil Neuroscience (VIGL) Stock Up 32% Today?
June 27, 2024
Vigil Neuroscience stock is up with heavy trading of VIGL shares this morning on news of a $40 million investment from Sanofi.
Via
InvestorPlace
Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine
June 26, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Sanofi Looks To Sell $20B Icy Hot Division: Likely Bidders Include Advent, PAI Partners, Blackstone, CVC
June 26, 2024
Sanofi wants $20 billion for its consumer health division, attracting interest from major firms like Advent and PAI Partners.
Via
Benzinga
Industry Groups Back GSK's Effort To Halt 70,000 Lawsuits Associated With Heartburn Drug Zantac Caused Cancer
June 20, 2024
GSK, supported by major industry groups, seeks to stop 70,000 Zantac lawsuits in Delaware, arguing a recent court ruling threatens the state's business-friendly reputation and judicial consistency.
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
Is It Too Late to Buy Novavax Stock?
June 14, 2024
Shares of the vaccine maker are trading up 230% this year.
Via
The Motley Fool
Why It's A New Day For COPD Patients — And Regeneron, Sanofi, Verona Stocks
June 13, 2024
The companies are closing in on the finish line for two new COPD treatments.
Via
Investor's Business Daily
Why Big-Name Biotech Regeneron Pharma Just Joined The 1,000-Club
June 12, 2024
Enthusiasm is growing for a looming approval in COPD treatment.
Via
Investor's Business Daily
A Life Expansion Revolution Is Coming: 3 Stocks That Could Lead the Charge
June 12, 2024
The integration of AI and healthcare is well underway.
Via
The Motley Fool
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Bull Market and Beyond: 3 Stocks Just Waiting to Soar
June 11, 2024
These pharma and biotech players could become long-term winners.
Via
The Motley Fool
Moderna Says Combination Flu And Covid Vaccine Beat Out Rivals From Sanofi, GSK
June 10, 2024
If approved, this would be the first combination vaccine based on mRNA technology to hit the market.
Via
Investor's Business Daily
Exposures
COVID-19
Meme Mania Meets Medicine: 3 Biotech Stocks Primed to Soar
June 07, 2024
These are the biotech stocks to buy for a meme rally as they represent companies with positive impending news related to clinical trials.
Via
InvestorPlace
The Dividend Darlings: 3 Stocks That Will Shower Your Portfolio with Cash
June 07, 2024
Dividend stocks have a record of stability and growth. Read here about three picks that are thriving and hiking dividends amid uncertainty.
Via
InvestorPlace
Sanofi Highlights Data From Blood Cancer Drug Sarclisa In New Diagnosed Multiple Myeloma Patients
June 04, 2024
Sanofi's phase 3 IMROZ study shows Sarclisa with VRd significantly improves progression-free survival in newly diagnosed, transplant-ineligible multiple myeloma patients.
Via
Benzinga
3 Dividend Stocks to Buy in June 2024 for Dependable Dividend Growth
June 03, 2024
Explore three reliable dividend growth stocks for June 2024 to expand your investment profits for the second half of the year.
Via
InvestorPlace
Zantac Heart Burn Continues For GSK As US Court Ruling Allows Thousands Of Zantac Lawsuits To Move Forward
June 03, 2024
GSK shares fell as the Delaware State Court allowed over 70,000 lawsuits regarding the discontinued heartburn drug Zantac (ranitidine) to proceed. This ruling contradicts a Federal Court's 2022...
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
Growth Stocks to Avoid Like the Plague: 3 Overpriced Picks Primed to Plummet
June 01, 2024
These are the overpriced growth stocks to sell and buy after these names corrected by 20% to 30% in the coming quarters.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
7
8
9
...
29
30
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.